Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Related Keywords

Amir Fathi , ,Resistance Profile ,Menin Inhibitor Ziftomenib ,Adults With ,Aml ,Acute Myeloid Leukemia ,Npm1 ,Npm1 Mutations ,Relapsed Refractory Aml ,Ziftomenib ,Novel Therapy ,Clinical Trial ,Safety Profile ,Adverse Events ,Drug Adverse Event ,Mrd Testing ,Minimal Residual Disease ,Menin Inhibitors ,Menin Inhibition ,Menin Resistance ,Resistance Mechanism ,Resistance Mutation ,Combination Therapy ,